Enrollment Milestone Achieved in MyPEAK™-1 and RIDGE™-1 Clinical Trials

August 6, 2025 - 23:19

Tenaya Therapeutics has announced significant progress in its clinical trials, marking a pivotal moment for its innovative therapies targeting specific heart conditions. The enrollment process for Cohorts 1 and 2 of the MyPEAK™-1 Phase 1b/2 trial of TN-201, aimed at treating MYBPC3-associated hypertrophic cardiomyopathy (HCM), has been successfully completed. This achievement has been bolstered by a positive safety review from the Data Safety Monitoring Board (DSMB), which has now allowed the company to proceed with the enrollment of expansion cohorts.

In addition, the RIDGE™-1 Phase 1b trial of TN-401 has also made strides, with Cohort 1 fully enrolled and the first patient with PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC) dosed in Cohort 2. This advancement follows the DSMB's recommendation to escalate dosing and expand the trial.

Tenaya Therapeutics is set to provide data readouts from both clinical programs in the fourth quarter of 2025, with a cash runway projected to extend into the second half of 2026, ensuring continued development of these promising therapies.